ArticleArXiv2024
Language Enhanced Model for Eye (LEME): An Open-Source Ophthalmology-Specific Large Language Model.
Article in ArXiv, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Large Language Models (LLMs) are poised to revolutionize healthcare. Ophthalmology-specific LLMs remain scarce and underexplored. We introduced an open-source, specialized LLM for ophthalmology, termed Language Enhanced Model for Eye (LEME). LEME was initially pre-trained on the Llama2 70B framework and further fine-tuned with a corpus of ~127,000 non-copyrighted training instances curated from ophthalmology-specific case reports, abstracts, and open-source study materials. We benchmarked LEME against eight other LLMs, namely, GPT-3.5, GPT-4, three Llama2 models (7B, 13B, 70B), PMC-LLAMA 13B, Meditron 70B, and EYE-Llama (another ophthalmology-specific LLM). Evaluations included four internal validation tasks: abstract completion, fill-in-the-blank, multiple-choice questions (MCQ), and short-answer QA. External validation tasks encompassed long-form QA, MCQ, patient EHR summarization, and clinical QA. Evaluation metrics included Rouge-L scores, accuracy, and expert evaluation of correctness, completeness, and readability. In internal validations, LEME consistently outperformed its counterparts, achieving Rouge-L scores of 0.20 ± 0.03 in abstract completion (all p<0.05), 0.82 ± 0.04 in fill-in-the-blank (all p<0.0001), and 0.22 ± 0.05 in short-answer QA (all p<0.0001, except versus GPT-4). In external validations, LEME excelled in long-form QA with a Rouge-L of 0.19 ± 0.01 (all p<0.0001), ranked second in MCQ accuracy (0.68 ± 0.09; all p<0.0001), and scored highest in EHR summarization and clinical QA (ranging from 4.24 to 4.83 out of 5 for correctness, completeness, and readability). LEME's emphasis on robust fine-tuning and the use of non-copyrighted data represents a breakthrough in open-source ophthalmology-specific LLMs, offering the potential to revolutionize execution of clinical tasks while democratizing research collaboration.
Identifiers
41031082PMC12478424What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.